Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 94 of the 96 references it cites were found in a registry or an index; 93 of the 158 sources its claims cite were checked for support.

From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy

Open access
Bozorgi, Vida, Babaahmadi, Mahnaz, Salehi, Mohammad, Vafaeimanesh, Jamshid, Hajizadeh-Saffar, Ensiyeh · 2025 · Stem Cell Research & Therapy

Abstract

Liver cirrhosis, a chronic disease distinguished by extensive scarring in the liver, results in liver dysfunction and fatal complications such as portal hypertension and liver cancer. Although early interventions can retard or reverse early injury, advanced stages often call for liver transplantation-a therapy undermined by donor shortage and logistical setbacks. Emerging cell therapies, particularly those based on mesenchymal stem cells (MSCs), offer a novel approach to addressing these clinical needs. MSCs, self-renewing multipotent stromal cells, can differentiate into many cell types, including hepatocyte-like cells. Immune regulation, regenerative signaling, and anti-scarring effects are three mechanisms that underlie their therapeutic promise. MSCs modulate immune cells, suppressing inflammation and promoting tissue healing. MSCs release several growth factors and cytokines, including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and matrix metalloproteinases (MMPs), which participate in tissue regeneration. Among these, HGF is bivalent, as it supports hepatocyte proliferation while also inhibiting fibrosis and apoptosis, thereby allowing the tissue to repair and protect itself. Recent advances identify extracellular vesicles from MSCs (MSC-EVs) as a cell-free alternative. The vesicles contain bioactive cargo, including microRNAs and proteins, that regulate immune function, inhibit cell death, and facilitate liver repair. Preclinical models of cirrhosis in animals have demonstrated MSC-EVs to enhance liver function, reduce scarring, and improve survival. This review integrates current knowledge of MSC-based therapies, their mechanisms, clinical potential, and challenges associated with their deployment. More than 50 clinical trials are registered or planned to evaluate MSC-based treatments for liver cirrhosis. Preclinical and clinical outcomes are encouraging; however, further work is needed to optimize delivery strategies, confirm safety, and facilitate the universal clinical use of this approach. Advances in MSC-guided regenerative medicine have the potential to revolutionize therapy for end-stage liver disease, offering hope where traditional treatments fail.

Overview

CoChat Summary

## TL;DR

This review argues that mesenchymal stem cells (MSCs) are a promising regenerative therapy for liver cirrhosis because they combine immunomodulatory, antifibrotic, and pro-regenerative effects, with encouraging preclinical and early clinical results. It also emphasizes that translation to routine care still depends on larger randomized trials, standardized protocols, and better delivery strategies.

## Key findings

  • The review states that more than 50 clinical trials are registered or planned to evaluate MSC-based treatments for liver cirrhosis.
  • In the cited meta-analysis, 14 clinical trials were reviewed, and MSC therapy plus standard supportive care was reported to significantly improve liver function in cirrhosis of various etiologies.
  • In an RCT of hepatitis B-related ACLF, intravenous BM-MSCs were associated with significant MELD improvement, reduced mortality, lower TNF-α and IL-6, and a significantly higher 24-week survival rate; the intervention was reported as safe with no severe adverse events.
  • In a study of autologous BM-MSCs for alcoholic cirrhosis, histology showed 25% and 37% reductions in collagen deposition after single and double infusions, respectively.

## Methods

  • This is a narrative review synthesizing mechanistic, preclinical, and clinical literature on MSC-based therapies for liver cirrhosis.
  • The paper draws on preclinical animal models (chemically induced, surgically induced, and genetically engineered) and clinical trials across multiple etiologies and MSC sources.
  • It summarizes outcomes using reported trial endpoints such as MELD score, fibrosis/collagen deposition, liver enzymes, albumin, survival, and adverse events.

## Limitations

  • The paper explicitly states that heterogeneity of trial designs, small numbers of studies, and short follow-up durations do not permit firm conclusions.
  • It also notes the need for larger, multicenter Phase III studies and standardized protocols to validate long-term efficacy and dosing.
  • Evident from the text: much of the clinical evidence cited is early-phase, heterogeneous, and source-/delivery-dependent, which makes cross-trial comparison difficult.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13287-025-04535-8

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Molecular mechanisms underpinning hepatic fibrosis. Chronic injury (viral, toxic, metabolic) triggers hepatocyte damage, releasing DAMPs and ROS. These activate Kupffer cells via TLR4/MyD88, driving NF-κB-dependent inflammation and NLRP3 inflammasome formation. Resultant cytokines (TNF-α, IL-1β) and PDGF recruit monocytes and activate HSCs. Quiescent HSCs transdifferentiate into collagen-producing myofibroblasts through TGF-β/Smad signaling (promoting COL1A1/COL3A1 transcription) and PDGF/ERK pathways (inducing proliferation). Impaired ECM degradation results from TIMP-1 overexpression inhibiting MMPs. Self-sustaining fibrogenic loops develop through cytokine cross-talk (e.g., TNF-α → NF-κB → TGF-β). MSC therapies target these pathways (e.g., HGF inhibition of TGF-βR, EV delivery of anti-fibrotic miRNAs). NAFLD: Nonalcoholic Fatty Liver Disease; TLRs: Toll-like receptors; NF-𝜅B: nuclear factor-κB; MyD88: Myeloid differentiation primary response 88; TNF-α: tumor necrosis factor-α; IL-1β: Interleukin-1β; ccl2: C-C motif chemokine ligand 2; TGF-β: Transforming growth factor β; PDGF: Platelet-Derived Growth Factor; ERK: extracellular-signal-regulated kinase; MAPK: mitogen-activated protein kinase; TIMPs: tissue inhibitors of metalloproteinases; MMPs: matrix metalloproteinase; HSC: Hepatic Stellate Cell
Fig. 1 Molecular mechanisms underpinning hepatic fibrosis. Chronic injury (viral, toxic, metabolic) triggers hepatocyte damage, releasing DAMPs and ROS. These activate Kupffer cells via TLR4/MyD88, driving NF-κB-dependent inflammation and NLRP3 inflammasome formation. Resultant cytokines (TNF-α, IL-1β) and PDGF recruit monocytes and activate HSCs. Quiescent HSCs transdifferentiate into collagen-producing myofibroblasts through TGF-β/Smad signaling (promoting COL1A1/COL3A1 transcription) and PDGF/ERK pathways (inducing proliferation). Impaired ECM degradation results from TIMP-1 overexpression inhibiting MMPs. Self-sustaining fibrogenic loops develop through cytokine cross-talk (e.g., TNF-α → NF-κB → TGF-β). MSC therapies target these pathways (e.g., HGF inhibition of TGF-βR, EV delivery of anti-fibrotic miRNAs). NAFLD: Nonalcoholic Fatty Liver Disease; TLRs: Toll-like receptors; NF-𝜅B: nuclear factor-κB; MyD88: Myeloid differentiation primary response 88; TNF-α: tumor necrosis factor-α; IL-1β: Interleukin-1β; ccl2: C-C motif chemokine ligand 2; TGF-β: Transforming growth factor β; PDGF: Platelet-Derived Growth Factor; ERK: extracellular-signal-regulated kinase; MAPK: mitogen-activated protein kinase; TIMPs: tissue inhibitors of metalloproteinases; MMPs: matrix metalloproteinase; HSC: Hepatic Stellate CellCC BY-NC-ND · PubMed Central
Fig. 2 Comparison of stem cell transplantation approaches (autologous vs. allogeneic) across the included clinical trials
Fig. 2 Comparison of stem cell transplantation approaches (autologous vs. allogeneic) across the included clinical trialsCC BY-NC-ND · PubMed Central
Fig. 3 Distribution of mesenchymal stem cell (MSC) sources (e.g., bone marrow, adipose tissue, umbilical cord) in the analyzed clinical trials
Fig. 3 Distribution of mesenchymal stem cell (MSC) sources (e.g., bone marrow, adipose tissue, umbilical cord) in the analyzed clinical trialsCC BY-NC-ND · PubMed Central
Fig. 4 Clinical trial phases (Phase I, II, III, IV, or combined phases) and their representation in the selected studies
Fig. 4 Clinical trial phases (Phase I, II, III, IV, or combined phases) and their representation in the selected studiesCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

60 Valid · 21 Not valid · 40 Not checked · 41 Own results and interpretations

58 more claims · 23 with their cited sources checked

Create a free account to see all 162 claims and to verify the 11 references still open.

See all claims — free account
  • It may state two separate claims as one. 89
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 96 references

Cited by

See all 11

Metadata

Authors
Bozorgi, V., Babaahmadi, M., Salehi, M., Vafaeimanesh, J., & Hajizadeh-Saffar, E.
Affiliations
  • Qom University of Medical Science and Health Services (IR)
  • Royan Institute (IR)
Corresponding author
Vafaeimanesh, Jamshid
Venue
Stem Cell Research & Therapy
Published
2025-08-05
Volume
16
Issue
1
Pages
421-421
ISSN
1757-6512 (ISSN-L)
OpenAlex
W4412991144
Cited by
11
References
96
Citations by year
2026: 9 · 2025: 2
FWCI
1.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
mesenchymal stem cells, liver cirrhosis, liver fibrosis, hepatocyte growth factor, extracellular vesicles, cell-free therapy, regenerative medicine, cell therapy, immune regulation, tissue regeneration, microRNA, clinical trials, end-stage liver disease, hepatocyte-like cells
MeSH terms
Animals, Clinical Trials as Topic, Humans, Liver Cirrhosis, Liver Regeneration, Signal Transduction, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy. https://app.cochat.ai/papers/10.1186/s13287-025-04535-8
The paper
Bozorgi, V., Babaahmadi, M., Salehi, M., Vafaeimanesh, J., & Hajizadeh-Saffar, E. (2025). From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-025-04535-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.